Centice Corporation, a pioneer in chemical verification and identification using Raman spectroscopy and computational sensor technology, announced today the availability of the new PINPOINT Rx™ system. Combining advanced spectroscopy hardware technology, analytical software and internal databases, PINPOINT Rx™ captures the spectral signature of a prescription drug and checks this signature against a known database.
“With its speed and accuracy, the PINPOINT Rx™ system demonstrates a new method for improving healthcare processes.”
PINPOINT Rx™ is designed to assist doctors and pharmacists in rapidly identifying whole pills, pills with no markings, fragments of pills, or other unknown chemical substances. The complete process is done in seconds and can be performed at the patient site using the small form factor PINPOINT Rx™. Today, most physicians or nurses send the unknown medication to the pharmacy where the pharmacist will compare the medication to a database of drugs containing shape, color and imprint information. If the unidentified pill does not have all the details on it (like imprints), then the pharmacist encounters challenges to discovering the exact drug; this can take valuable time and is not always accurate. PINPOINT Rx™ combines a spectral database and an imprint database, making it a one stop solution for all drug identification needs.
"Centice Corporation is an industry leader in chemical identification and verification. It is another market opportunity where we can apply our technology in an area that can and will save lives," said Centice Corporation CEO, Scott Albert. "With its speed and accuracy, the PINPOINT Rx™ system demonstrates a new method for improving healthcare processes."
SOURCE Centice Corporation